Navid Redjal, MD, FAANS


Cooper University Health Care Titles

  • Director, Surgical Neuro-Oncology
  • Neurosurgeon

Cooper Medical School of Rowan University Titles

  • Assistant Professor of Neurological Surgery

Board Certifications

  • American Board of Neurological Surgery

Other Languages

Farsi, Spanish

Professional Type

Cooper and Inspira Neuroscience / Cooper University Physician



About Me

Dr. Navid Redjal has joined the Cooper Neuroscience Institute as the Director of Surgical Neuro-oncology. Dr. Redjal currently serves as Director of Neurosurgical Oncology at Capital Health System and will provide surgical neuro-oncology care at both campuses, further enhancing the existing collaboration in clinical neuroscience between Cooper University Care and Capital Health. At Cooper, he joins the Neurosurgery team in building a neuro-oncology center of excellence with a focus on the highest quality patient care in combination with cutting edge treatment and exciting clinical trials.
Dr. Navid Redjal is a board certified neurosurgeon specializing in the treatment of brain tumors with extensive research and clinical background in neuro-oncology. Dr. Redjal graduated from Harvard Medical School with honors, specifically completing the Harvard-MIT Health Sciences and Technology Society curriculum with research thesis focusing on targeted therapeutics for brain cancer with a post-doctoral research fellowship at the Dana Farber Cancer Institute. After completing medical school, he did his residency at the Massachusetts General Hospital/Harvard neurosurgery program where he also did an enfolded fellowship in stereotactic radiosurgery. He specializes in complex brain surgery including awake surgery, language and motor mapping, minimally invasive neuro-endoscopic surgery utilizing detailed MRI-based neuro-navigation with diffuse tensor imaging and intraoperative ultrasound. He also uses stereotactic radiosurgery (e.g. Gamma Knife) in collaboration with radiation oncologists to treat a variety of brain and spine tumors.

Office Locations

Cooper Multispecialty Center at Camden Campus

Three Cooper Plaza
Suite 104
Camden , NJ 08103
Phone: 856.968.8695
Fax: 856.968.8206
Maps & Directions

Education & Training

Medical SchoolHarvard Medical School, Boston, MA
InternshipGeneral Surgery - Massachusetts General Hospital, Boston, MA
ResidencyNeurological Surgery - Massachusetts General Hospital, Boston, MA
FellowshipStereotactic Proton Radiosurgery - Massachusetts General Hospital, Boston, MA


  • American Association of Neurological Surgeons
  • Congress of Neurological Surgeons
  • Society for Neuro-Oncology
  • American Society of Clinical Oncology


Redjal, N., Venteicher, A. S., Dang, D., Sloan, A., Kessler, R. A., Baron, R. R., Hadjipanayis, C. G., Chen, C. C., Ziu, M., Olson, J. J., & Nahed, B. V. (2021). Guidelines in the management of CNS tumors. Journal of neuro-oncology, 151(3), 345–359.

Redjal, N., Nahed, B. V., Dietrich, J., Kalkanis, S. N., & Olson, J. J. (2020). Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults. Journal of neuro-oncology, 150(2), 165–213.

Redjal, N., Zhu, Y., & Shah, K. (2015). Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem cells (Dayton, Ohio), 33(1), 101–110.

Redjal, N., Reinshagen, C., Le, A., Walcott, B. P., McDonnell, E., Dietrich, J., & Nahed, B. V. (2016). Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. Journal of neuro-oncology, 127(3), 505–514.

Nahed, B. V., Redjal, N., Brat, D. J., Chi, A. S., Oh, K., Batchelor, T. T., Ryken, T. C., Kalkanis, S. N., & Olson, J. J. (2015). Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. Journal of neuro-oncology, 125(3), 609–630.